We have come to an end (for now) of our exploration of the regulatory data available at the time of licensing the vaccine at the end of 2020 and, in a few cases, afterwards. As we covered a lot of ground, we summarise the posts and their content in one-liners in several “posts of posts” to allow readers to get to the bottom line.
The first three posts we…